Affiliation:
1. çukurova üniversitesi
2. ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ
3. CUKUROVA UNIVERSITY
Abstract
Purpose: This study aimed to compare the effectiveness and toxicity of neoadjuvant dual Human epidermal growth factor receptor-2 (HER-2) blockade combined with chemotherapy in advanced breast cancer.
Materials and Methods: Patients with HER2-positive breast cancer who received trastuzumab (T)+ pertuzumab (P) with weekly neoadjuvant paclitaxel or docetaxel were included in the study. Patients’ age, clinical stage, histological reports, ki-67 index, toxicity profiles, and the state of the pathological and radiological response following neoadjuvant therapy were evaluated.
Results: All 40 patients were women (mean age 50.9) and the overall rate of pathological complete responses was 62.5% (25/40). The rates of non-responsive patients and grade 2 neuropathy were statistically significantly higher in the group receiving P+T+Weekly Paclitaxel. When SUV values were analyzed based on hormone positivity, it was found that they decreased dramatically in both groups and were statistically significant. The logistic regression analysis developed to predict the precise response status to therapy was found to be significant.
Conclusion: When comparing the agents used in dual HER-2 targeted therapies, patient response rates and toxicity profiles may differ. Ductal carcinoma in situ (DCIS) and molecular subtype were found to be significant variables in the developed logistic regression model.
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference18 articles.
1. Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27:4-18.
2. Yang YL, Fan Y, Lang RG, Gu F, Fu L. Association of HER2 genetic heterogeneity with clinicopathological characteristics in breast cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010;27:540-5.
3. Schroeder RL, Stevens CL, Sridhar J. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Molecules. 2014;19:15196-212.
4. Osborne CK, Schiff R, Rimawi M. DE-escalating treatment for her2-positive early breast cancer. Trans Am Clin Climatol Assoc. 2020;131:119-26.
5. Yu L, Fu F, Li J, Huang M, Zeng B, Lin Y et al. Dual HER2 blockade versus a single agent in trastuzumab-containing regimens for HER2-positive early breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Oncol. 2020;2020:5169278.